Article Text

This article has a correction. Please see:

Download PDFPDF
Extended report
Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy
  1. R E Alten1,
  2. C Zerbini2,
  3. S Jeka3,
  4. F Irazoque4,
  5. F Khatib5,
  6. P Emery6,
  7. A Bertasso7,
  8. M Rabbia7,
  9. J P Caulfield8
  1. 1
    Schlosspark-Klinik, Internal Medicine, Rheumatology, Teaching Hospital Charite, University Medicine, Berlin, Germany
  2. 2
    Hospital Heliopolis, Servico de Reumatologia, São Paulo, Brazil
  3. 3
    NZOZ “Nasz Lekarz”, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną, Toruń, Poland
  4. 4
    Servicio de Reumatología, CMN 20 de Noviembre, ISSSTE, México
  5. 5
    Clinresco Centres (Pty) Ltd, Arwyp Medical Suites, Kempton Park, South Africa
  6. 6
    Chapel Allerton Hospital, Rheumatology Research Department, Leeds, UK
  7. 7
    Hoffmann-La Roche, Nutley, New Jersey, USA
  8. 8
    Roche Palo Alto, LLC, Palo Alto, California, USA
  1. Correspondence to R E Alten, Schlosspark-Klinik, Internal Medicine, Rheumatology, Teaching Hospital Charite, University Medicine, Heubnerweg 2, Berlin, Germany 14059; rieke.alten{at}


Objective: To determine the efficacy and safety of pamapimod in adult patients with active rheumatoid arthritis (RA) who had an inadequate clinical response to methotrexate (MTX).

Methods: Patients receiving stable doses of MTX were randomised to one of six dose groups and received 12 weeks of double-blind pamapimod (up to 300 mg once daily) or matching placebo. The primary efficacy measure was the proportion of patients with ⩾20% improvement in RA based on the American College of Rheumatology criteria (ACR20) at 12 weeks. Secondary measures were ACR50, Disease Activity Score (DAS)/European League Against Rheumatism (EULAR) responses and the individual ACR core set of parameters. Safety measures included adverse events (AEs), laboratory testing and immunology assessments.

Results: On a background of MTX, the percentage of patients with an ACR20 response at week 12 in the pamapimod groups (31% to 43%) was not significantly different from placebo (34%). Secondary efficacy end points showed a similar pattern. AEs were typically mild and included infections, gastrointestinal disturbances, dizziness and rashes; AEs resulting in discontinuation of study drug were primarily attributed to infections.

Conclusion: In patients with active RA receiving stable doses of MTX, pamapimod showed non-significant improvement in efficacy outcomes compared to placebo.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was funded by Hoffmann-La Roche (Nutley, New Jersey, USA) and managed by Roche personnel (in Nutley and Palo Alto, California, USA). The study was designed by clinicians and scientists at Roche with input from the investigators. Data were collected by the investigators and entered into a database maintained by Roche. The data were analysed by Roche statisticians and programmers.

  • Competing interests None.

  • Ethics approval Each site obtained approval from their associated ethics committee. Roche did not supply drug without proof of approval.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism